Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus TRI MILI.
BRIELLYN vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive